Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells

British Journal of Haematology

Volumn 163, Issue 2, 2013, Pages 182-193

  Klitgaard, Josephine L ^a,b,d   Koefoed, Klaus ^a   Geisler, Christian ^b   Gadeberg, Ole V ^c   Frank, David A ^d,e,f   Petersen, Jørgen ^a   Jurlander, Jesper ^b   Pedersen, Mikkel W ^a  

^a Symphogen AS   (Denmark)

^b Rigshospitalet   (Denmark)

^c LILLEBAELT HOSPITAL   (Denmark)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antibody combinations; CD5; Chronic lymphocytic leukaemia; Complement dependent cytotoxicity; Epitope binning

Indexed keywords

ALEMTUZUMAB; CD5 ANTIGEN; CHIMERIC CD5 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; OFATUMUMAB; RECOMBINANT CD5 MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; INTERNALIZATION; MONOTHERAPY; PRIORITY JOURNAL;

ANTIBODY COMBINATIONS; CD5; CHRONIC LYMPHOCYTIC LEUKAEMIA; COMPLEMENT-DEPENDENT CYTOTOXICITY; EPITOPE BINNING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTIGENS, CD5; CELL LINE, TUMOR; CELL SURVIVAL; CHROMOSOME ABERRATIONS; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED;

EID: 84884990167     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12503     Document Type: Article

References (50)

1. Andersen, C.R., Nielsen, L.S., Baer, A., Tolstrup, A.B. & Weilguny, D. (2011) Efficient expression from one CMV enhancer controlling two core promoters. Molecular Biotechnology, 48, 128-137.
2. Bikah, G., Lynd, F.M., Aruffo, A.A., Ledbetter, J.A. & Bondada, S. (1998) A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5. International Immunology, 10, 1185-1196.
3. Calvo, J., Padilla, O., Places, L., Vigorito, E., Vila, J.M., Vilella, R., Mila, J., Vives, J., Bowen, M.A. & Lozano, F. (1999) Relevance of individual CD5 extracellular domains on antibody recognition, glycosylation and co-mitogenic signalling. Tissue Antigens, 54, 16-26.
4. Coiffier, B., Lepretre, S., Pedersen, L.M., Gadeberg, O., Fredriksen, H., van Oers, M.H., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., Walewski, J., Flensburg, M., Petersen, J. & Robak, T. (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood, 111, 1094-1100.
5. Dechant, M., Weisner, W., Berger, S., Peipp, M., Beyer, T., Schneider-Merck, T., Lammerts van Bueren, J.J., Bleeker, W.K., Parren, P.W., van de Winkel, J.G. & Valerius, T. (2008) Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Research, 68, 4998-5003.
6. Dillman, R.O., Shawler, D.L., Dillman, J.B. & Royston, I. (1984) Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. Journal of Clinical Oncology, 2, 881-891.
7. Doronina, S.O., Toki, B.E., Torgov, M.Y., Mendelsohn, B.A., Cerveny, C.G., Chace, D.F., DeBlanc, R.L., Gearing, R.P., Bovee, T.D., Siegall, C.B., Francisco, J.A., Wahl, A.F., Meyer, D.L. & Senter, P.D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology, 21, 778-784.
8. Elliott, E.V., Pindar, A., Stevenson, F.K. & Stevenson, G.T. (1978) Synergistic cytotoxic effects of antibodies directed against different cell surface determinants. Immunology, 34, 405-409.
9. Foss, F.M., Raubitscheck, A., Mulshine, J.L., Fleisher, T.A., Reynolds, J.C., Paik, C.H., Neumann, R.D., Boland, C., Perentesis, P., Brown, M.R., Frincke, J.M., Lollo, C.P., Larson, S.M. & Carrasquillo, J.A. (1998) Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clinical Cancer Research, 4, 2691-2700.
10. Garza-Garcia, A., Esposito, D., Rieping, W., Harris, R., Briggs, C., Brown, M.H. & Driscoll, P.C. (2008) Three-dimensional solution structure and conformational plasticity of the N-terminal scavenger receptor cysteine-rich domain of human CD5. Journal of Molecular Biology, 378, 129-144.
11. Ge, X., Wu, L., Hu, W., Fernandes, S., Wang, C., Li, X., Brown, J.R. & Qin, X. (2011) rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clinical Cancer Research, 17, 6702-6711.
12. Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A. & Introna, M. (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood, 98, 3383-3389.
13. Günther, S. (2005) Development of a CHO-DG44 cell line for production of recombinant polyclonal antibodies. Institut für Biochemie und Biotechnologie, Vol. Master Technische Universität Braunschweig, Germany.
14. Hainsworth, J.D., Litchy, S., Barton, J.H., Houston, G.A., Hermann, R.C., Bradof, J.E. & Greco, F.A. (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 21, 1746-1751.
15. Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A.J. & Waldmann, H. (1983) Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood, 62, 873-882.
16. Hale, G., Clark, M. & Waldmann, H. (1985) Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. Journal of Immunology, 134, 3056-3061.
17. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
18. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grunhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Buhler, A., Winkler, D., Zenz, T., Bottcher, S., Ritgen, M., Mendila, M., Kneba, M., Dohner, H. & Stilgenbauer, S. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 1164-1174.
19. Hardy, R.R. & Hayakawa, K. (1994) CD5 B cells, a fetal B cell lineage. Advances in Immunology, 55, 297-339.
20. Hertler, A.A., Schlossman, D.M., Borowitz, M.J., Laurent, G., Jansen, F.K., Schmidt, C. & Frankel, A.E. (1988) A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. Journal of Biological Response Modifiers, 7, 97-113.
21. Hughes-Jones, N.C., Gorick, B.D. & Howard, J.C. (1983) The mechanism of synergistic complement-mediated lysis of rat red cells by monoclonal IgG antibodies. European Journal of Immunology, 13, 635-641.
22. Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B. & Rai, K.R. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, 3554-3561.
23. Koefoed, K., Steinaa, L., Soderberg, J.N., Kjaer, I., Jacobsen, H.J., Meijer, P.J., Haurum, J.S., Jensen, A., Kragh, M., Andersen, P.S. & Pedersen, M.W. (2011) Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. mAbs, 3, 584-595.
24. Leahy, D.J., Dann, C.E. 3rd, Longo, P., Perman, B. & Ramyar, K.X. (2000) A mammalian expression vector for expression and purification of secreted proteins for structural studies. Protein Expression and Purification, 20, 500-506.
25. Levy, R. & Miller, R.A. (1983) Biological and clinical implications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. Annual Review of Medicine, 34, 107-116.
26. Lim, S.H., Vaughan, A.T., Ashton-Key, M., Williams, E.L., Dixon, S.V., Chan, H.T., Beers, S.A., French, R.R., Cox, K.L., Davies, A.J., Potter, K.N., Mockridge, C.I., Oscier, D.G., Johnson, P.W., Cragg, M.S. & Glennie, M.J. (2011) Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood, 118, 2530-2540.
27. Liu, Z., Hazan-Halevy, I., Harris, D.M., Li, P., Ferrajoli, A., Faderl, S., Keating, M.J. & Estrov, Z. (2011) STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells. Molecular Cancer Research, 9, 507-515.
28. Loisel, S., Andre, P.A., Golay, J., Buchegger, F., Kadouche, J., Cerutti, M., Bologna, L., Kosinski, M., Viertl, D., Delaloye, A.B., Berthou, C., Mach, J.P. & Boumsell, L. (2011) Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia. Molecular Cancer, 10, 42.
29. Martin, P.J., Hansen, J.A., Siadak, A.W. & Nowinski, R.C. (1981) Monoclonal antibodies recognizing normal human T lymphocytes and malignant human B lymphocytes: a comparative study. Journal of Immunology, 127, 1920-1923.
30. McAlister, M.S., Brown, M.H., Willis, A.C., Rudd, P.M., Harvey, D.J., Aplin, R., Shotton, D.M., Dwek, R.A., Barclay, A.N. & Driscoll, P.C. (1998) Structural analysis of the CD5 antigen-expression, disulphide bond analysis and physical characterisation of CD5 scavenger receptor superfamily domain 1. European Journal of Biochemistry, 257, 131-141.
31. Meijer, P.J., Andersen, P.S., Haahr Hansen, M., Steinaa, L., Jensen, A., Lantto, J., Oleksiewicz, M.B., Tengbjerg, K., Poulsen, T.R., Coljee, V.W., Bregenholt, S., Haurum, J.S. & Nielsen, L.S. (2006) Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. Journal of Molecular Biology, 358, 764-772.
32. Miller, R.A. & Levy, R. (1981) Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet, 2, 226-230.
33. Niculescu-Duvaz, I. (2010) Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2 + metastatic breast cancer. Current Opinion in Molecular Therapeutics, 12, 350-360.
34. Osterborg, A., Dyer, M.J., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D. & Mellstedt, H. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 15, 1567-1574.
35. Pawluczkowycz, A.W., Beurskens, F.J., Beum, P.V., Lindorfer, M.A., van de Winkel, J.G., Parren, P.W. & Taylor, R.P. (2009) Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. Journal of Immunology, 183, 749-758.
36. Pedersen, M.W., Jacobsen, H.J., Koefoed, K., Hey, A., Pyke, C., Haurum, J.S. & Kragh, M. (2010) Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Research, 70, 588-597.
37. Perez-Chacon, G., Vargas, J.A., Jorda, J., Morado, M., Rosado, S., Martin-Donaire, T., Losada-Fernandez, I., Rebolleda, N. & Perez-Aciego, P. (2007) CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC. Leukemia Research, 31, 183-193.
38. Polito, L., Bolognesi, A., Tazzari, P.L., Farini, V., Lubelli, C., Zinzani, P.L., Ricci, F. & Stirpe, F. (2004) The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. Leukemia, 18, 1215-1222.
39. Rosen, S.T., Zimmer, A.M., Goldman-Leikin, R., Gordon, L.I., Kazikiewicz, J.M., Kaplan, E.H., Variakojis, D., Marder, R.J., Dykewicz, M.S. & Piergies, A. (1987) Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. Journal of Clinical Oncology, 5, 562-573.
40. Royston, I., Majda, J.A., Baird, S.M., Meserve, B.L. & Griffiths, J.C. (1980) Human T cell antigens defined by monoclonal antibodies: the 65, 000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. Journal of Immunology, 125, 725-731.
41. Rozman, C. & Montserrat, E. (1995) Chronic lymphocytic leukemia. New England Journal of Medicine, 333, 1052-1057.
42. Shawler, D.L., Miceli, M.C., Wormsley, S.B., Royston, I. & Dillman, R.O. (1984) Induction of in vitro and in vivo antigenic modulation by the anti-human T-cell monoclonal antibody T101. Cancer Research, 44, 5921-5927.
43. Shawler, D.L., Johnson, D.E., McCallister, T.J., Bartholomew, R.M. & Dillman, R.O. (1988) Mechanisms of human CD5 modulation and capping induced by murine monoclonal antibody T101. Clinical Immunology and Immunopathology, 47, 219-229.
44. Siena, S., Bregni, M., Formosa, A., Brando, B., Marenco, P., Lappi, D.A., Bonadonna, G. & Gianni, A.M. (1989) Immunotoxin-mediated inhibition of chronic lymphocytic leukemia cell proliferation in humans. Cancer Research, 49, 3328-3332.
45. Tallarida, R.J. (2006) An overview of drug combination analysis with isobolograms. Journal of Pharmacology and Experimental Therapeutics, 319, 1-7.
46. Teeling, J.L., French, R.R., Cragg, M.S., van den Brakel, J., Pluyter, M., Huang, H., Chan, C., Parren, P.W., Hack, C.E., Dechant, M., Valerius, T., van de Winkel, J.G. & Glennie, M.J. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood, 104, 1793-1800.
47. Van de Velde, H. & Thielemans, K. (1996) Native soluble CD5 delivers a costimulatory signal to resting human B lymphocytes. Cellular Immunology, 172, 84-91.
48. White, C.A., Weaver, R.L. & Grillo-Lopez, A.J. (2001) Antibody-targeted immunotherapy for treatment of malignancy. Annual Review of Medicine, 52, 125-145.
49. Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmann, A., Robak, T., Furman, R.R., Hillmen, P., Trneny, M., Dyer, M.J., Padmanabhan, S., Piotrowska, M., Kozak, T., Chan, G., Davis, R., Losic, N., Wilms, J., Russell, C.A. & Osterborg, A. (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1749-1755.
50. Wierda, W.G., Kipps, T.J., Durig, J., Griskevicius, L., Stilgenbauer, S., Mayer, J., Smolej, L., Hess, G., Griniute, R., Hernandez-Ilizaliturri, F.J., Padmanabhan, S., Gorczyca, M., Chang, C.N., Chan, G., Gupta, I., Nielsen, T.G. & Russell, C.A. (2011) Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood, 117, 6450-6458.